Clinical trials: Linezolid
Bacterial Infection
Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin and skin structure infections in adults.
- Trial name
- NCT00633152
- Testing
- ceftaroline, linezolid, Aztreonam
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Forest Laboratories
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Acute Bacterial Skin and Skin Structure Infections
Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
This is a phase III, multi-center, randomized, active-comparator, study in subjects with ABSSSI. The study has two subgroups for assessment of efficacy and safety - oral subgroup 1 and IV subgroup 2.
- Trial name
- NCT03405064
- Testing
- Oral Levonadifloxacin/Linezolid Tablet, Intravenous Levonadifloxacin/Linezolid Infusion
- Where
- 32 sites in India
- Volunteers
- 501 people
- Sponsor
- Wockhardt
Bacterial Infections
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
This study is aimed to evaluate the efficacy and safety between Tedizolid 200mg daily (intra venous) I.V. to oral for 6-day treatment compared with that of Linezolid 600mg twice daily I.V.
- Trial name
- NCT02066402
- Testing
- Tedizolid (BAY119-2631), Linezolid
- Where
- 55 sites in United States, China and 2 more
- Volunteers
- 598 people
- Sponsor
- Bayer
Complicated Skin and Skin Structure Infections
Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)
The purpose of this study is to determine the clinical efficacy, safety, and tolerability of a 250 mg BID oral dose of JNJ-32729463 compared with linezolid in subjects with complicated skin and skin structure infections (cSSSIs).
- Trial name
- NCT01128530
- Testing
- JNJ-32729463, linezolid
- Where
- 27 sites in United States
- Volunteers
- 161 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Skin Diseases, Bacterial, Gram-Positive Bacterial Infections
Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
The purpose of this study is to determine whether contezolid acefosamil is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
- Trial name
- NCT03747497
- Testing
- contezolid acefosamil, linezolid 600 mg
- Where
- 7 sites in United States
- Volunteers
- 196 people
- Sponsor
- MicuRx
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Community Acquired Pneumonia
A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic…
- Trial name
- NCT02269644
- Testing
- Dalbavancin, Linezolid, Azithromycin
- Where
- United States
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Optic Nerve Diseases
Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater
To understand and characterize the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for six weeks or longer for the development of signs or symptoms of visual…
- Trial name
- NCT00359632
- Testing
- Zyvox - linezolid, Matched control
- Where
- 12 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Diabetic Foot Infection
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects…
- Trial name
- NCT05369052
- Testing
- contezolid acefosamil (IV)/contezolid (PO), Linezolid (IV and PO)
- Where
- 14 sites in United States, Bulgaria and 6 more
- Volunteers
- 865 people
- Sponsor
- MicuRx
Burns
Evaluation Of Linezolid Pk Profile In Burns Patients
Evaluation of linezolid pk profile in burns patients
- Trial name
- NCT00255996
- Testing
- linezolid
- Where
- 3 sites in France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Pneumonia
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
This is a study of safety and effectiveness of ceftaroline fosamil in children with Complicated Community-acquired Pneumonia receiving antibiotic therapy in the hospital.
- Trial name
- NCT01669980
- Testing
- Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
- Where
- 21 sites in United States, Argentina and 2 more
- Volunteers
- 40 people
- Sponsor
- Forest Laboratories
Tuberculosis, Multidrug-Resistant
Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)
This study is to evaluate the effectiveness and safety of a 9-month MDR-END regimen as a treatment for fluoroquinolone-sensitive multidrug resistant pulmonary tuberculosis in the real-world clinical setting.
- Trial name
- NCT06674291
- Testing
- No intervention (observational study)
- Volunteers
- 222 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Pneumonia
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia
The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.
- Trial name
- NCT01819935
- Testing
- linezolid (Zyvox), vancomycin
- Volunteers
- 5,271 people
- Sponsor
- Pfizer
Skin Infections, Bacterial
GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
This study will determine the safety, tolerability and efficacy of GSK1322322 verses Linezolid in subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
- Trial name
- NCT01209078
- Testing
- GSK1322322, Linezolid
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Skin and Subcutaneous Tissue Bacterial Infections
TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
This is a randomized, double-blind, double dummy, multicenter Phase 3 study of oral TR-701 FA 200 mg once daily for 6 days versus oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults.
- Trial name
- ABSSSI (NCT01170221)
- Testing
- TR-701 FA, Linezolid
- Where
- 84 sites in United States, Argentina and 9 more
- Volunteers
- 667 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Gram-Positive Bacterial Infections, Skin and Connective Tissue Diseases
Time To Efficacy and Onset Of Action Of Linezolid
To assess the onset of action of linezolid
- Trial name
- NCT00147511
- Testing
- linezolid
- Volunteers
- 118 people
- Sponsor
- Pfizer
Healthy Volunteers
Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects
The purpose of this study is to estimate the bioequivalence comparing Linezolid 600 MG Oral Suspension with 600 MG tablet in Chinese healthy male subjects. This study data will be used to support Linezolid OS NDA in China.
- Trial name
- NCT01055769
- Testing
- Linezolid
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Skin Diseases, Infectious
Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
A Phase III trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).
- Trial name
- CSSI (NCT00865280)
- Testing
- PTK 0796, linezolid, moxifloxacin
- Where
- 7 sites in United States
- Volunteers
- 143 people
- Sponsor
- Paratek Pharmaceuticals Inc